GlassScriptPhysician profile
Lance M Dicker
NPI 1902022817
$2,331.41
in general payments reported to CMS, 2019-2025
22 companies · $896 in 2025
The $896 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $81.69 · 2021: $112 · 2022: $327 · 2023: $284 · 2024: $334 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491 · Education: $23.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.36 |
| Education | $23.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $285.17 | 2019-2025 | Farxiga |
| Vantive US Healthcare LLC | $278.68 | 2025 | Renal - Pd |
| Vifor Pharma, INC. | $236.37 | 2019-2025 | Veltassa |
| Nxstage Medical, INC. | $225.05 | 2025 | Nxstage Pureflow Solution, Nxstage Cartridge Express, Nxstage System One |
| Amgen INC. | $211.51 | 2019-2025 | Tavneos, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $168.98 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $143.58 | 2019-2025 | Liberty Select Cycler |
| Baxter Healthcare | $125.00 | 2024 | |
| Travere Therapeutics, INC. | $96.24 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $94.66 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $83.09 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $75.22 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $74.60 | 2023-2025 | Terlivaz |
| Glaxosmithkline, LLC. | $39.40 | 2022-2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $35.67 | 2019-2024 | Ultomiris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $30.61 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.19 | 2019 | |
| Ani Pharmaceuticals, INC. | $25.78 | 2025 | Purified Cortrophin Gel |
| Lundbeck LLC | $22.23 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.82 | 2024 | Lupkynis |
| Boston Scientific Corporation | $15.74 | 2021 | |
| Ardelyx, INC. | $14.82 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Dicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.